s Investigation of Reported Anaphylaxis Post COVID-19 Vaccination in Subjects with History of Allergies and Anaphylaxis

Background: Two mRNA COVID-19 vaccines, Pfizer-BioNTech and Moderna, are currently approved in the United States, and one viral-vector vaccine, J&J/Janssen, is authorized for limited use. The Vaccine Adverse Event Reporting System (VAERS) database gathers reports of adverse effects, including anaphylaxis.Objective: In this manuscript, we provide a summary of reported incidence of anaphylaxis rates following administration of the two mRNA and one viral-vector COVID-19 vaccine.Methods: A detailed investigation of the relative risk of anaphylaxis for recipients with or without a prior history of allergy and/or anaphylaxis is also described.Results: Overall reported incidence of anaphylaxis is 4.49 [95% CI: 0.25 128;“ 8.73] cases per million doses administered.Conclusion: The reported risk of anaphylaxis is 1.83 times greater for recipients with prior allergies and no anaphylaxis but 17.70 times greater for recipients with prior allergies and anaphylaxis.